Fort Washington Investment Advisors Inc. OH lowered its position in Celgene Corporation (NASDAQ:CELG) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 81,141 shares of the biopharmaceutical company’s stock after selling 1,841 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Celgene Corporation were worth $10,538,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Thompson Davis & CO. Inc. raised its stake in shares of Celgene Corporation by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Celgene Corporation during the first quarter worth approximately $118,000. Motco raised its stake in shares of Celgene Corporation by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the last quarter. Penserra Capital Management LLC purchased a new stake in shares of Celgene Corporation during the second quarter worth approximately $129,000. Finally, Acropolis Investment Management LLC purchased a new stake in shares of Celgene Corporation during the second quarter worth approximately $144,000. Institutional investors own 79.16% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/18/fort-washington-investment-advisors-inc-oh-trims-holdings-in-celgene-corporation-celg.html.
In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 20,227 shares of company stock worth $2,843,956. Company insiders own 0.95% of the company’s stock.
CELG has been the subject of several analyst reports. Morgan Stanley cut Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research note on Thursday, October 5th. BTIG Research restated a “hold” rating on shares of Celgene Corporation in a research note on Sunday, October 22nd. Cantor Fitzgerald restated a “hold” rating and set a $112.00 price target on shares of Celgene Corporation in a research note on Monday, October 30th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a research note on Monday, October 23rd. Finally, Citigroup Inc. cut Celgene Corporation from a “buy” rating to a “neutral” rating in a research note on Friday, October 20th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the stock. Celgene Corporation presently has a consensus rating of “Buy” and a consensus price target of $139.87.
Celgene Corporation (NASDAQ:CELG) opened at $104.10 on Friday. The company has a market capitalization of $81,370.00, a PE ratio of 15.45, a PEG ratio of 0.76 and a beta of 1.79. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $1.58 EPS. equities research analysts anticipate that Celgene Corporation will post 6.67 earnings per share for the current year.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.